U087 - Dermatologic Findings in the Stem Cell Transplant Patient
Monday, March 4; 4:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Summarize the step required and the methods use when a patient undergoes a stem cell transplant.
- Identify common dermatology findings in the immediate post-transplant period.
- Diagnose chronic skin finding that occur after a stem cell transplant.
Increasing numbers of patients are undergoing stem cell transplants. This session will discuss the methods and medications used when a patient undergoes a stem cell transplant. Skin findings in the immediate post-transplant period will be discussed including challenges in differentiating the common eruptions. The session will conclude with a discussion on chronic graft verses host disease.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.
- Anadkat, Milan J., MD: AnaptysBio – I(Grants/Research Funding); BestDoctors – C(H); Biogen – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); InflaRx GmbH – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Novocure – C(Fees); OnQuality Pharmaceuticals, Ltd. – C(Fees);
- Musiek, Amy C., MD: Actelion – A(H), I(OB), SP(H); Elorac, Inc. – I(OB); Kyowa Hakko Kirin Pharma, Inc. – A(H), I(OB); miRagen Therapeutics, Inc. – I(OB); Pfizer Inc. – I(OB); Seattle Genetics – A(H); Solgenix, Inc. – I(OB);
Dr. Musiek / Acute skin finding in the SCT patient
Dr. Anadkat / Chronic skin findings in the SCT patient